New Zealand markets closed

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.93-0.10 (-1.11%)
At close: 4:00PM EDT
8.98 +0.05 (+0.56%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.03
Open8.89
Bid8.80 x 900
Ask8.98 x 2900
Day's range8.53 - 9.00
52-week range2.54 - 35.20
Volume673,156
Avg. volume1,018,207
Market cap573.767M
Beta (5Y monthly)0.09
PE ratio (TTM)N/A
EPS (TTM)-1.23
Earnings date05 Nov 2021 - 09 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est28.43
  • Motley Fool

    Does This Biotech Have the Secret to Conquering Covid Variants?

    Gritstone Bio (NASDAQ: GRTS) is far from being the first to the coronavirus vaccine finish line. The biotech company's vaccine candidate just began phase 1 trials this year. Gritstone's clinical trials are in the earliest stage.

  • GlobeNewswire

    Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the Compensation Committee of the company’s Board of Directors has granted six employees nonqualified stock options to purchase an aggregate of 41,800 shares of its common stock with an exercise price of $11.58, which is equal to the closing price of Gritstone’s commo

  • GlobeNewswire

    Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer

    GRT-R910, a self-amplifying mRNA (SAM) SARS-CoV-2 vaccine, delivers antigens from both the spike protein and highly conserved non-spike proteins for broad protection across variants Induction of CD8+ T cells in addition to neutralizing antibody responses offers potential for robust and persistent immunity, especially in at-risk populations (eg older individuals and those who are immunocompromised) Initial Phase 1 data from this study are expected in the first Quarter 2022 EMERYVILLE, Calif., Sep